NCT01434524

Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids

The Evaluation About the Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Kochi University · Academic / Other
• Sex: All
• Age: 16 Years – 90 Years
• Healthy volunteers: Accepted

Summary

The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear. The aim of this study is to assess the impact of oral supplementation with BCAA on the prevention for the development of liver tumorigenesis in patients undergoing liver resection.

Detailed description

This study might demonstrate a tendency of the improvement in the cumulative tumor recurrence rate after hepatectomy for liver neoplasm in the Livact group compared to that in the Control Group. The investigators believe that BCAA seems to be a remarkable benefit for liver resection, especially on its reduction in the recurrence of liver cancer. This treatment regimen has potential to offer benefits for clinical use selectively, especially for patients with chronic liver diseases.

Conditions

• Liver Cancer

Interventions

Type	Name	Description
DRUG	LIVACT	LIVACT contains 13.0 g of free amino acids

Timeline

• Start date: 2007-04-01
• Primary completion: 2008-10-01
• Completion: 2011-06-01
• First posted: 2011-09-15
• Last updated: 2011-09-15

Locations

1 site across 1 country: Japan